Lisata Therapeutics, Inc. (LSTA) AI Stock Analysis
LSTA AI stock analysis summary
AI ResearchLisata Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on cellular therapies for conditions like critical limb ischemia and coronary microvascular dysfunction. The company generated trailing twelve months revenue of $100,000 with an operating margin of -16426.0%. As of June 30, 2026, it held $10.4M in cash and short-term investments with negative enterprise value of -$5.9M.
- Market cap
- $11.1M
- Revenue (TTM)
- $100,000
- P/E
- — fwd 2.7x
- 1Y return
- -59.1% S&P 500 16.8%
- Avg. target
- $4.00 288.3% vs last close
Bull case
- The consensus analyst price target of $4.00 indicates potential upside of 288.3% relative to the last close of $1.03.
- The balance sheet carries $10.4M in cash and short-term investments with a current ratio of 3.69 as of June 30, 2026.
- Lisata beat quarterly earnings expectations in 3 of the past 4 quarters while narrowing its annual net loss to -$16.6M in FY2025.
Bear case
- Revenue declined by 83.0% in FY2025 to $170,000 and fell a further 90.0% year-over-year in the quarter ended June 30, 2026.
- The business continues to consume liquidity, posting negative free cash flow of -$16.0M in FY2025.
- Long-term shareholders have experienced heavy dilution, with the 5-year share count expanding by 128.5% alongside a 5-year return of -94.4%.
What Lisata Therapeutics does
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing cellular therapies aimed at reversing disease and promoting tissue regeneration. Its pipeline includes HONEDRA, which holds SAKIGAKE designation and is in Phase II clinical trials for critical limb ischemia. The company is also evaluating XOWNA in Phase IIb trials for coronary microvascular dysfunction and CLBS201, a CD34+ cell therapy for pre-dialysis patients with chronic kidney disease. Incorporated in 1980 and formerly known as NeoStem and Caladrius Biosciences, the company is based in Basking Ridge, New Jersey.
Growth and profitability
In FY2025, Lisata Therapeutics generated revenue of $170,000, down 83.0% from $1.0M in FY2024 and down from $121.4M in FY2022. Net income stood at -$16.6M in FY2025, compared to -$20.0M in FY2024 and -$54.2M in FY2022. Operating margin was -10711.2% in FY2025, while gross margin contracted to 14.1% from 100.0% in FY2024. For the trailing twelve months ended June 30, 2026, revenue was $100,000, accompanied by an operating margin of -16426.0% and diluted EPS of -$1.64. In the latest quarter, quarterly revenue growth declined 90.0% year-over-year.
Balance sheet and cash flow
As of June 30, 2026, Lisata Therapeutics reported cash and short-term investments of $10.4M and total assets of $11.0M against shareholders' equity of $8.2M. The company maintains a current ratio of 3.69. In FY2025, operating cash flow was -$15.9M, free cash flow was -$16.0M, and capital expenditures totaled $28,000. lisata does not pay dividends or repurchase stock, and its share count grew 128.5% over the past 5 years.
Valuation and performance
At a last close of $1.03, Lisata Therapeutics had a market cap of $11.1M and an enterprise value of -$5.9M. The stock trades at a price-to-sales multiple of 111.3x, significantly above the median of 4.1x for its US-listed Healthcare peers. Its price-to-book ratio is 1.9x, while forward P/E stands at 2.7x compared to the peer median of 17.3x. Over the past year, the stock fell 59.1%, while the S&P 500 gained 16.8%. Over 5 years, the stock returned -94.4% against 83.0% for the S&P 500.
What analysts expect
Lisata Therapeutics has 2 Hold ratings and zero Buy or Sell ratings from Wall Street analysts. The consensus mean price target is $4.00, representing an implied upside of 288.3% over the last close of $1.03. For the current fiscal year ending December 31, 2026, analysts estimate an EPS of -$1.09 and revenue of $0. For the following fiscal year, the consensus EPS estimate is -$1.16 on $0 revenue. The company beat EPS estimates in 3 of the last 4 quarters, with its next earnings date scheduled for November 5, 2026.
Key risks and what to watch
- Annual cash burn of -$15.9M in operating cash flow presents ongoing financing risk relative to the $10.4M cash reserve as of June 30, 2026.
- Analysts project $0 in revenue for both the fiscal year ending December 31, 2026, and the following fiscal year.
- The stock has traded down 66.1% versus its 200-day average and remains close to its 52-week low of $0.98.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this LSTA AI stock analysis
This page is an AI-written research summary of Lisata Therapeutics, Inc. (LSTA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: LSTA income statement, LSTA balance sheet, LSTA key metrics, LSTA analyst forecast, LSTA chart. See the LSTA stock overview for the latest quote and news.
LSTA AI stock analysis FAQ
Does Lisata Therapeutics pay a dividend?
No, Lisata Therapeutics does not pay a dividend and has no dividend yield reported.
What is the cash balance of Lisata Therapeutics?
As of June 30, 2026, Lisata Therapeutics held $10.4M in cash and short-term investments, with total assets of $11.0M.
What is the consensus analyst target for LSTA?
The mean analyst price target is $4.00, which is 288.3% above its October 16, 2026 closing price of $1.03.
When is Lisata Therapeutics reporting earnings next?
The company is scheduled to report its next financial results on November 5, 2026.